Diagnostic reproducibility of tumour budding in colorectal cancer: A multicentre, multinational study using virtual microscopy

Histopathology

Volumn 61, Issue 4, 2012, Pages 562-575

  Puppa, Giacomo ^a   Senore, Carlo ^b   Sheahan, Kieran ^c   Vieth, Michael ^d   Lugli, Alessandro ^e   Zlobec, Inti ^e   Pecori, Sara ^f   Wang, Lai Mun ^g   Langner, Cord ^h   Mitomi, Hiroyuki ⁱ   Nakamura, Takatoshi ^j   Watanabe, Masahiko ^j   Ueno, Hideki ^k   Chasle, Jacques ^l   Conley, Stephen A ^m   Herlin, Paulette ⁿ   Lauwers, Gregory Y ^m   Risio, Mauro ^o  

^a 'G Fracastoro' City Hospital   (Italy)

^b CPO Piemonte   (Italy)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^d INSTITUTE OF PATHOLOGY   (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

^f UNIVERSITY OF VERONA   (Italy)

^g JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁱ JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^l Calvados Cancer General Registry   (France)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁿ UNIVERSITÉ DE CAEN   (France)

^o CANDIOLO CANCER INSTITUTE   (Italy)

more..

Author keywords

Colorectal cancer; Reproducibility; Tumour budding; Virtual microscopy

Indexed keywords

CYTOKERATIN; CYTOKERATIN AE1; CYTOKERATIN AE2; CYTOKERATIN AE3; EOSIN; HEMATOXYLIN; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER STAGING; CANCER TISSUE; COLORECTAL CANCER; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROSCOPY; PATHOLOGIST; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SURGEON; TELEMEDICINE; TISSUE STRUCTURE; TUMOR BUDDING; VIRTUAL MICROSCOPY; CLINICAL TRIAL; COLORECTAL TUMOR; MULTICENTER STUDY; OBSERVER VARIATION; PATHOLOGY; PROCEDURES; TELEPATHOLOGY;

COLORECTAL NEOPLASMS; HUMANS; MICROSCOPY; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; TELEPATHOLOGY;

EID: 84871925029     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04270.x     Document Type: Review

References (52)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010; 127; 2893-2917.
2. Burke HB. Outcome prediction and the future of the TNM staging system. J. Natl Cancer Inst. 2004; 96; 1408-1409.
3. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl Cancer Inst. 2004; 96; 1420-1425.
4. Puppa G, Sonzogni A, Colombari R, Pelosi G. TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. Arch. Pathol. Lab. Med. 2010; 134; 837-852.
5. Wang LM, Kevans D, Mulcahy H et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer.Am. J. Surg. Pathol. 2009; 33; 134-141.
6. Ohike N, Coban I, Kim GE et al. Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas.Am. J. Surg. Pathol. 2010; 34; 1417-1424.
7. Yamaguchi Y, Ishii G, Kojima M et al. Histopathologic features of the tumor budding in adenocarcinoma of the lung: tumor budding as an index to predict the potential aggressiveness.J. Thorac. Oncol. 2010; 5; 1361-1368.
8. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor 'budding' in patients with colorectal cancer. Dis. Colon Rectum 1993; 36; 627-635.
9. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002; 40; 127-132.
10. Choi HJ, Park KJ, Shin JS, Roh MS, Kwon HC, Lee HS. Tumor budding as a prognostic marker in stage-III rectal carcinoma. Int.J. Colorectal Dis. 2007; 22; 863-868.
11. Losi L, Ponti G, Gregorio CD et al. Prognostic significance of histological features and biological parameters in stage I (pT1and pT2) colorectal adenocarcinoma. Pathol. Res. Pract. 2006;202; 663-670.
12. Morodomi T, Isomoto H, Shirouzu K, Kakegawa K, Irie K, Morimatsu M. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 1989; 63; 539-543.
13. Ogawa T, Yoshida T, Tsuruta T et al. Tumor budding is predictive of lymphatic involvement and lymph node metastases in
14. Okuyama T, Oya M, Ishikawa H. Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma.J. Surg. Oncol. 2003; 83; 42-47.
15. Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II well-differentiated or moderately differentiated colon adenocarcinoma. Dis. Colon Rectum 2003; 46; 1400-1406.
16. Park SY, Choe G, Lee HS, Jung SY, Park JG, Kim WH. Tumor budding as an indicator of isolated tumor cells in lymph nodes from patients with node-negative colorectal cancer. Dis. Colon Rectum 2005; 48; 292-302.
17. Ohtsuki K, Koyama F, Tamura T et al. Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res. 2008; 28; 1831-1836.
18. Okuyama T, Oya M, Ishikawa H. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma. Dis. Colon Rectum 2002; 45; 628-634.
19. Hase K, Shatney CH, Mochizuki H et al. Long-term results of curative resection of 'minimally invasive' colorectal cancer. Dis. Colon Rectum 1995; 38; 19-26.
20. Hori H, Fujimori T, Fujii S et al. Evaluation of tumor cell dissociation as a predictive marker of lymph node metastasis in submucosal invasive colorectal carcinoma. Dis. Colon Rectum 2005; 48; 938-945.
21. Ishikawa Y, Kishima-Fukasawa Y, Ito K, Akasaka Y, Yokoo T, Ishii T. Histopathologic determinants of regional lymph node metastasis in early colorectal cancer. Cancer 2008; 112; 924-933.
22. Kazama S, Watanabe T, Ajioka Y, Kanazawa T, Nagawa H. Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2. Br. J. Cancer 2006; 94;293-298.
23. Okuyama T, Oya M, Yamaguchi M. Budding (sprouting) as a useful prognostic marker in colorectal mucinous carcinoma. Jpn.J. Clin. Oncol. 2002; 32; 412-416.
24. Sohn DK. Chang HJ, Park JW et al. Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type. J. Clin.Pathol. 2007; 60; 912-915.
25. Suzuki A, Togashi K, Nokubi M et al. Evaluation of venous invasion by Elastica van Gieson stain and tumor budding predicts local and distant metastases in patients with T1 stage colorectal cancer. Am. J. Surg. Pathol. 2009; 33; 1601-1607.
26. Ueno H, Price AB, Wilkinson KH, Jass JR, Mochizuki H, Talbot IC.A new prognostic staging system for rectal cancer. Ann. Surg.2004; 240; 832-839.
27. Wang HS, Liang WY, Lin TC et al. Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and longterm prognosis. Dis. Colon Rectum 2005; 48; 1182-1192.
28. Yasuda K. Inomata M, Shiromizu A, Shiraishi N, Higashi H, Kitano S. Risk factors for occult lymph node metastasis of colorectal cancer invading the submucosa and indications for endoscopic mucosal resection. Dis. Colon Rectum 2007; 50;1370-1376.
29. Nakamura T, Mitomi H, Kikuchi S, Ohtani Y, Sato K. Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepatogastroenterology 2005; 52; 1432-1435.
30. Jass JR, O'Brien J, Riddell RH, Snover DC. Recommendations for the reporting of surgically resected specimens of colorectal carcinoma: Association of Directors of Anatomic and Surgical Pathology. Am. J. Clin. Pathol. 2008; 129; 13-23.
31. Kanazawa H, Mitomi H, Nishiyama Y et al. Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis. 2008; 10; 41-47.
32. Nakamura T. Mitomi H, Kanazawa H, Ohkura Y, Watanabe M. Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis. Colon Rectum 2008; 51; 568-572.
33. Shinto E, Jass JR, Tsuda H et al. Differential prognostic significance of morphologic invasive markers in colorectal cancer:tumor budding and cytoplasmic podia. Dis. Colon Rectum 2006;49; 1422-1430.
34. Zlobec I, Molinari F, Martin V et al. Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J. Gastroenterol. 2010; 16; 4823-4831.
35. Turner RR, Li C, Compton CC. Newer pathologic assessment techniques for colorectal carcinoma. Clin. Cancer Res. 2007; 13;6871s-6876s.
36. Ueno H, Mochizuki H, Hashiguchi Y et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004; 127; 385-394.
37. Prall F, Nizze H, Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology 2005; 47;17-24.
38. Prall F, Ostwald C. High-degree tumor budding and podiaformation in sporadic colorectal carcinomas with K-ras gene mutations. Hum. Pathol. 2007; 38; 1696-1702.
39. Shinto E, Mochizuki H, Ueno H, Matsubara O, Jass JR. A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci. Histopathology 2005; 47; 25-31.
40. Puppa G, Risio M, Sheahan K et al. Standardization of whole slide image morphologic assessment with definition of a new application:digital slide dynamic morphometry. J. Pathol. Inform. 2011;2; 48.
41. Sobin LH, Wittekind C eds. TNM classification of malignant tumors,6th edn. New York, NY: Wiley-Liss, 2002.
42. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007; 50; 151-162.
43. Fleiss JL. Statistical methods for rates and proportions. Chichester:John Wiley & Sons, 1981.
44. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33; 159-174.
45. Hayes BD, Maguire A, Conlon N, Gibbons D, Wang LM, Sheahan K. Reproducibility of the rapid bud count method for assessment of tumor budding in stage II colorectal cancer. Am. J. Surg.Pathol. 2010; 34; 746-748.
46. Bosman FT, Carneiro F, Hruban RH eds. Tumours of the colon and rectum. World Heath Organization classification of tumours of the digestive system. Lyon: IARC, 2010; 131-182.
47. Sy J, Fung CL, Dent OF, Chapuis PH, Bokey L, Chan C. Tumor budding and survival after potentially curative resection of node-positive colon cancer. Dis. Colon Rectum 2010; 53; 301-307.
48. Farris AB, Misdraji J, Srivastava A et al. Sessile serrated adenoma: challenging discrimination from other serrated colonic polyps. Am. J. Surg. Pathol. 2008; 32; 30-35.
49. Terry MB, Neugut AI, Bostick RM, Potter JD, Haile RW, Fenoglio-Preiser CM. Reliability in the classification of advanced colorectal adenomas. Cancer Epidemiol. Biomarkers Prev. 2002; 11; 660-663.
50. Risio M, Bussolati G, Senore C et al. Virtual microscopy for histology quality assurance of screen-detected polyps. J. Clin.Pathol. 2010; 63; 916-920.
51. Ajioka Y, Watanabe H, Kazama S et al. Early colorectal cancer with special reference to the superficial nonpolypoid type from a histopathologic point of view. World J. Surg. 2000; 24; 1075-1080.
52. Jass JR, Barker M, Fraser L et al. APC mutation and tumour budding in colorectal cancer. J. Clin. Pathol. 2003; 56; 69-73.